US2010105692A1PendingUtilityA1
Dipterinyl Calcium Pentahydrate (DCP) and Therapeutic Methods Based Thereon
Est. expiryOct 30, 2026(~0.3 yrs left)· nominal 20-yr term from priority
A61P 35/00C07D 475/04A61P 31/00A61P 37/00
51
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Provided herein is dipterinyl calcium pentahydrate (DCP) and therapeutic methods based thereon. Also provided herein is the compound dipterinyl calcium pentahydrate (DCP) or an analog or polymorph thereof.
Claims
exact text as granted — not AI-modified1 .- 3 . (canceled)
4 . A method of treating disease in a subject comprising the administration of a therapeutically effective amount of a compound of formula (I):
M(pterin) x (H2O) y wherein: M is a bivalent metal ion selected from the group consisting of Ca 2+ , Cu 2+ , Mg 2+ , V 2+ , Cr 2+ , Mn 2+ , Fe 2+ , Mo 2+ , Zn 2+ , Sr 2+ , Ba 2+ , Ra 2+ , Ru 2+ , Rh 2+ , Pd 2+ , Cd 2+ , Sn 2+ , W 2+ , Re 2+ , Os 2+ , Ir 2+ , Pt 2+ , Si 2+ , and Sm 2+ ; X is an integer from 1 to 8; and y is an integer of from 1 to 8.
5 . The method of claim 4 wherein the compound of formula (I) is dipterinyl calcium pentahydrate (DCP).
6 . The method of claim 5 wherein the disease is a neoplastic disease.
7 . The method of claim 5 wherein the disease is an infectious disease.
8 . The method of claim 6 comprising modulating tryptophan degradation.
9 . The method of claim 6 comprising modulating neopterin production.
10 . The method of claim 6 comprising modulating IFN-γ production.
11 . The method of claim 6 comprising modulating the activity of the enzyme IDO.
12 . The method of claim 6 comprising modulating immune resistance in human solid tumors.
13 .- 21 . (canceled)Join the waitlist — get patent alerts
Track US2010105692A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.